AustinPx Capacity Update July 2024: Small Molecule Finished Dosage Form

AustinPx was founded to help developers realize the full potential of their drug candidates. There are many obstacles to bringing a drug to market, including poor bioavailability and accelerated timelines. That’s where we come in. Our client-centric approach is designed to simplify the complexity of outsourcing and our team of formulation, analytical and manufacturing experts work with you to overcome challenges and identify opportunities to do more, faster.

As the inventors of KinetiSol™ Technology, a next-generation amorphous solid dispersion (ASD) technology for poorly soluble APIs, with its smaller footprint, broader design space, and greener processing solutions, we aim to disrupt the ASD industry. From poor solubility to accelerated timelines, drug development is inherently complex. Effective communication and flexible processes can simplify your path to the market. That is why AustinPx has developed a client-centric approach to contract development and manufacturing services. We are driven by our client’s success and intentional about differentiating ourselves through flexibility and responsiveness, and consultative, unbiased, solutions-driven development services.